Skip to content

Stanford researchers invent nanotech microchip to diagnose type-1 diabetes.

An inexpensive, portable, microchip-based test for diagnosing type-1 diabetes could improve patient care worldwide and help researchers better understand the disease, according to the device’s inventors at the Stanford University School of Medicine.

The test employs nanotechnology to detect type-1 diabetes outside hospital settings. The handheld microchips distinguish between the two main forms of diabetes mellitus, which are both characterized by high blood-sugar levels but have different causes and treatments. Until now, making the distinction has required a slow, expensive test available only in sophisticated health-care settings. The researchers are seeking Food and Drug Administration approval of the device.

With the new test, not only do the team anticipate being able to diagnose diabetes more efficiently and more broadly, the medical community will also understand diabetes better, both the natural history and how new therapies impact the body.  Better testing is needed because recent changes in who gets each form of the disease have made it risky to categorize patients based on their age, ethnicity or weight, as was common in the past, and also because of growing evidence that early, aggressive treatment of type-1 diabetes improves patients’ long-term prognoses. Decades ago, type-1 diabetes was diagnosed almost exclusively in children, and type-2 diabetes almost always in middle-aged, overweight adults. The distinction was so sharp that lab confirmation of diabetes type was usually considered unnecessary, and was often avoided because of the old test’s expense and difficulty. Now, because of the childhood obesity epidemic, about a quarter of newly diagnosed children have type-2 diabetes. And, for unclear reasons, a growing number of newly diagnosed adults have type-1.

Type-1 diabetes is an autoimmune disease caused by an inappropriate immune-system attack on healthy tissue. As a result, patients’ bodies stop making insulin, a hormone that plays a key role in processing sugar. The disease begins when a person’s own antibodies attack the insulin-producing cells in the pancreas. The auto-antibodies are present in people with type-1 but not those with type-2, which is how tests distinguish between them.

A growing body of evidence suggests that rapid detection of, and aggressive new therapies for, type-1 diabetes benefit patients in the long run, possibly halting the autoimmune attack on the pancreas and preserving some of the body’s ability to make insulin.

The old, slow test detected the auto-antibodies using radioactive materials, took several days, could only be performed by highly-trained lab staff and cost several hundred dollars per patient. In contrast, the microchip uses no radioactivity, produces results in minutes, and requires minimal training to use. Each chip, expected to cost about $20 to produce, can be used for upward of 15 tests. The microchip also uses a much smaller volume of blood than the older test; instead of requiring a lab-based blood draw, it can be done with blood from a finger prick.

The microchip relies on a fluorescence-based method for detecting the antibodies. The team’s innovation is that the glass plates forming the base of each microchip are coated with an array of nanoparticle-sized islands of gold, which intensify the fluorescent signal, enabling reliable antibody detection. The test was validated with blood samples from people newly diagnosed with diabetes and from people without diabetes. Both groups had the old test and the microchip-based test performed on their blood.

In addition to new diabetics, people who are at risk of developing type-1 diabetes, such patients’ close relatives, also may benefit from the test because it will allow doctors to quickly and cheaply track their auto-antibody levels before they show symptoms. Because it is so inexpensive, the test may also allow the first broad screening for diabetes auto-antibodies in the population at large.

The team state that the auto-antibodies are a crystal ball.  Even if the patient doesn’t have diabetes yet, if they have one auto-antibody linked to diabetes in their blood, they are at significant risk; with multiple auto-antibodies, it’s more than 90 percent risk.

With the new nanotech-based MEMS there is great potential to capture people before they develop the disease, and prevent diabetes or prevent its complications by starting therapy early.  But the old test was prohibitive for that type of thinking because it was so costly and time-consuming.

Stanford University have filed for a patent on the microchip, and the researchers also are working to launch a startup company to help get the method approved by the FDA and bring it to market, both in the United States and in parts of the world where the old test is too expensive and difficult to use.

Source:  The Stanford University School of Medicine

A plasmonic chip for biomarker discovery and diagnosis of type 1 diabetes.  Schematic depicting the spatial relationship of the platform's PEG layer, the islet-specific antigens, the primary autoantibodies (Abs) from diluted human serum or blood and the detection antibodies conjugated with a fluorophore signal.  Feldman et al 2014.
A plasmonic chip for biomarker discovery and diagnosis of type 1 diabetes. Schematic depicting the spatial relationship of the platform’s PEG layer, the islet-specific antigens, the primary autoantibodies (Abs) from diluted human serum or blood and the detection antibodies conjugated with a fluorophore signal. Feldman et al 2014.

Healthinnovations View All

Michelle Petersen is the founder of Healthinnovations, having worked in the health and science industry for over 21 years, which includes tenure within the NHS and Oxford University. Healthinnovations is a publication that has reported on, influenced, and researched current and future innovations in health for the past decade.

Michelle has been picked up as an expert writer for Informa publisher’s Clinical Trials community, as well as being listed as a blog source by the world’s leading medical journals, including the acclaimed Nature-Springer journal series.

Healthinnovations is currently indexed by the trusted Altmetric and PlumX metrics systems, respectively, as a blog source for published research globally. Healthinnovations is also featured in the world-renowned BioPortfolio, BioPortfolio.com, the life science, pharmaceutical and healthcare portal.

Most recently the Texas A&M University covered The Top 10 Healthinnovations series on their site with distinguished Professor Stephen Maren calling the inclusion of himself and his team on the list a reflection of “the hard work and dedication of my students and trainees”.

Michelle Petersen’s copy was used in the highly successful marketing campaign for the mega-hit film ‘Jumanji: The Next Level, starring Jack Black, Karen Gilian, Kevin Hart and Dwayne ‘The Rock’ Johnson. Michelle Petersen’s copywriting was part of the film’s coverage by the Republic TV network. Republic TV is the most-watched English language TV channel in India since its inception in 2017.

An avid campaigner in the fight against child sex abuse and trafficking, Michelle is a passionate humanist striving for a better quality of life for all humans by helping to provide traction for new technologies and techniques within healthcare.

7 thoughts on “Stanford researchers invent nanotech microchip to diagnose type-1 diabetes. Leave a comment

  1. We absolutely love your blog and find almost all of your post’s to be exactly what I’m looking for.
    Do you offer guest writers to write content available foor you?
    I wouldn’t mind creating a post or elaborating on a number of the subjects you write
    regarding here. Again, awesome site!

  2. Havee you ever thought about wrriting an ebook or guest authoring on other blogs?

    I have a blog based upon oon the same information you discuss
    and would love to have you sbare some stories/information. I
    know my audience would value your work. If you
    arre even remotely interested, feel free to shoot me an e-mail.

  3. I can appreciate this! It’s difficult to find decent, well-written articles lately. Almost everyone seems to have some type of agenda. Anyway, I’ve bookmarked your blog and will sent it to my friends as well. Would love to see more blogs on this. Thanks again.

  4. , HbA1c is used to monitor how a pateint who already has diabetes is managing it. If you were to do a HbA1c on a newly diagnosed type 1, then they probably wouldn’t have an elevated level as the symptoms are rapid. However, a newly diagnosed type 2 who has had symptoms for months (or years sometimes) may have an elevated HbA1c because their diabetes hasn’t been picked up and is therefore not controlled. Hope that helped to clarify.

  5. Fantastic web site. Lots of helpful information here. I’m
    sending it to several buddies ans additionally sharing in delicious.
    And naturally, thanks on your effort!

Leave a Reply

Translate »